Naropin (ropivacaine hydrochloride Injection recall
FDA recall D-0727-2026 · initiated Jul 16, 2026
Fresenius Kabi USA, LLC recalled Naropin (ropivacaine hydrochloride Injection in Jul 2026 — an FDA Class II recall (D-0727-2026) because Presence of Particulate Matter: Hair was found in products.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Presence of Particulate Matter: Hair was found in products
Something got into the product
A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 92,600 vials
Details
- Product
- Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
- Recalling company
- Fresenius Kabi USA LLC
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- Nationwide within in the USA
- Initiated
- Jul 16, 2026
- FDA report date
- Jul 29, 2026
This recall is linked to a product we cover: Naropin →
Frequently asked
- Was Naropin (ropivacaine hydrochloride Injection recalled?
- Fresenius Kabi USA, LLC recalled Naropin (ropivacaine hydrochloride Injection in Jul 2026 — an FDA Class II recall (D-0727-2026) because Presence of Particulate Matter: Hair was found in products. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Naropin (ropivacaine hydrochloride Injection recalled?
- Per the FDA enforcement record, the reason for recall D-0727-2026 was: Presence of Particulate Matter: Hair was found in products
- Is a recalled Naropin (ropivacaine hydrochloride Injection dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Naropin (ropivacaine hydrochloride Injection are affected?
- Distributed: Nationwide within in the USA. The recall covers these lots — Lot #: 6133436, Exp. Date 10/2028. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0727-2026.